Pharmaceutical company Orion Biotechnology Canada Ltd reported on Monday that it received feedback from the Food and Drug Administration (FDA) to facilitate the preparation and submission of the Pre-Investigational New Drug (PIND) application of its lead candidate OB-002O in 2020.
The company added that the PIND was focused on the development of OB-002O as an agent for the treatment of solid tumours. The OB-002 is a chemokine analogue CCR5 antagonist that is being developed in a topical form for HIV prevention (OB-002H) as well as an intravenous immunotherapy agent (OB-002O).
According to the company, CCR5 antagonism has been shown to induce anti-cancer effects in preclinical and Phase 1 clinical studies of colorectal cancer (Halama et al. Cancer Cell 2016) and is an active area of cancer drug development.
In conjunction, the use of OB-002 alone, or in combination with a checkpoint inhibitor, was efficacious in the CT-26 syngeneic colorectal cancer model, which provided the rationale for this Pre-IND submission, concluded the company .
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma